Sparsentan: A First-in-Class Dual Endothelin and Angiotensin II Receptor Antagonist

CONCLUSION: Sparsentan reduces proteinuria in IgAN and FSGS, and has expedited approval by the FDA for IgAN in patients at risk of rapid disease progression, generally at urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g. Interim results from PROTECT and results from DUET showed promise for improving proteinuria in IgAN and FSGS. Long-term renal function benefit and safety data are pending.PMID:37706310 | DOI:10.1177/10600280231198925
Source: The Annals of Pharmacotherapy - Category: Drugs & Pharmacology Authors: Source Type: research